CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and effo ...

Cumulative anthracycline dose is expressed as doxorubicin equivalent. Patients with no exposure to anthracyclines and carrying CBR3:GA/AA genotype served as the reference group. Magnitude of risk is ...

SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, a new analysis of a ...

Chen said that while patients with this type of breast cancer generally receive either adjuvant taxane-based regimens or taxane- and anthracycline-based regimens, there is limited data to guide ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

"Although anthracycline cardiotoxicity has been known about for decades, effective preventive therapies have been lacking due to limited knowledge of the mechanisms involved," explained study ...

On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc.

The study, published in JACC: CardioOncology, demonstrates that treatment with the SGLT2 inhibitor empagliflozin can mitigate the cardiac injury associated with anthracycline therapy ...

CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo ...